These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 21144000)
1. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000 [TBL] [Abstract][Full Text] [Related]
2. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476 [TBL] [Abstract][Full Text] [Related]
3. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells. Ogino Y; Sato A; Uchiumi F; Tanuma SI Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for resistance to diverse classes of NAMPT inhibitors. Wang W; Elkins K; Oh A; Ho YC; Wu J; Li H; Xiao Y; Kwong M; Coons M; Brillantes B; Cheng E; Crocker L; Dragovich PS; Sampath D; Zheng X; Bair KW; O'Brien T; Belmont LD PLoS One; 2014; 9(10):e109366. PubMed ID: 25285661 [TBL] [Abstract][Full Text] [Related]
5. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells. Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913 [TBL] [Abstract][Full Text] [Related]
11. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer. Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303 [TBL] [Abstract][Full Text] [Related]
12. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881 [TBL] [Abstract][Full Text] [Related]
14. Fragment-based discovery of a potent NAMPT inhibitor. Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958 [TBL] [Abstract][Full Text] [Related]
15. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer. Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976 [TBL] [Abstract][Full Text] [Related]
16. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772 [TBL] [Abstract][Full Text] [Related]
17. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells. Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909 [TBL] [Abstract][Full Text] [Related]
18. Nicotinamide Phosphoribosyltransferase Inhibitor APO866 Prevents IL-1β-Induced Human Nucleus Pulposus Cell Degeneration via Autophagy. Shi C; Wu H; Du D; Im HJ; Zhang Y; Hu B; Chen H; Wang X; Liu Y; Cao P; Tian Y; Shen X; Gao R; van Wijnen AJ; Ye X; Yuan W Cell Physiol Biochem; 2018; 49(6):2463-2482. PubMed ID: 30261504 [TBL] [Abstract][Full Text] [Related]
19. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies. Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141 [TBL] [Abstract][Full Text] [Related]